Cyclo Therapeutics Inc (CYTH)

[ksuave]

News at 8:

CTD Holdings Receives Large Order From Brazil for Trappsol Cyclo(TM) Which May Provide Benefit in Many Lysosomal Storage Diseases

Mar 22, 2010
Mar 22, 2010
HIGH SPRINGS, FL
MARKETWIRE

CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) today announced
that a significant order has been placed by a Brazilian healthcare
organization for Trappsol Cyclo(TM) for the experimental treatment of
Niemann Pick Type C (NPC) disease. Currently, there are approximately
a dozen children in Brazil diagnosed with NPC disease, a rare genetic
cholesterol transport disorder that causes severe neurological
effects in infants, children and adults.

"There is no known cure for Niemann Pick Type C disease, nor is there
any FDA approved treatment for this debilitating and relentlessly
progressive condition," said Rick Strattan, CEO of CTD Holdings, Inc.
"Trappsol Cyclo(TM) is showing promise in NPC afflicted experimental
animals, and many international doctors treating NPC patients are
expressing interest in the compound as a potential life extending
therapy. Patients with the fatal condition have no other options
currently."

In April 2009, Trappsol Cyclo(TM) was approved under compassionate
use by the U.S. Food and Drug Administration (FDA) to treat Addi and
Cassi Hempel, identical twin girls suffering from NPC disease.
Medi-ports, similar to those used to administer chemotherapy drugs,
were surgically placed into the twins' chest walls which allowed
doctors to continuously infuse Trappsol Cyclo(TM). In March 2010, the
Hempel family filed an Orphan Drug Application with the FDA for
Trappsol Cyclo(TM) as the treatment for NPC. The family is also
working with doctors to determine the most efficacious route of
administration for the Trappsol Cyclo(TM).

"There is hope that cyclodextrin can not only help treat NPC disease,
but there is solid evidence that other lysosomal storage diseases
(LSD) can be treated," added Strattan.

About Niemann Pick Type C diseases

NPC disease is one of at least 42 rare, fatal diseases which are
classed as lysosomal storage diseases (LSD). The disease is
characterized by cellular accumulation of lipids, in particular,
unesterified cholesterol and glycosphingolipids, in most cells of the
body including brain, liver and spleen. Treatment with Cyclo(TM) has
been shown to delay clinical disease onset, to reduce intraneuronal
storage, secondary markers of neurodegeneration, and significantly
increase lifespan in NPC mice.

About CTD Holdings, Inc.

CTD Holdings, Inc. is a one-stop shop, business-to-business
facilitator of commercial and research applications of Cyclodextrins.
With its branded Trappsol(R), Aquaplex(R) and Cyclo(TM) product
offerings, CTDH scientists coordinate the development of commercial
products for use in many diverse industries that endeavor to put non
water-soluble ingredients into water-based formulations for direct
use or conversion into stable, easy to use powders.
This news release contains "forward-looking statements" that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the
forward-looking statements. CTDH is timely in the filing of its SEC
mandated financial reports; these filings also contain
forward-looking statements. The above forward-looking statements are
made as of the date above; CTD Holdings, Inc accepts no specific
responsibility for updating such statements.

For More Information:
Rick Strattan
CTD Holdings
1-386-454-0887
Email Contact
SOURCE: CTD, Inc.
(TS:CDJ;CTDH;)